The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The main treatment goals in LR-MDS and how these differ from HR-MDS
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the primary treatment goals in lower-risk myelodysplastic syndromes (LR-MDS), emphasizing the focus on quality of life and symptom improvement, particularly anemia and transfusion dependence. With new approvals like luspatercept and imetelstat, treatment now aims for more effective outcomes, such as achieving higher hemoglobin levels rather than just transfusion independence. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
